EGI
HBIO icon

EAM Global Investors’s Harvard Bioscience HBIO Stock Holding History

EAM Global Investors’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,450
Closed -$1.02M – 141
2018
Q3 		$1.02M Buy
+19,450
New +$1.09M 0.41% 130

Other funds holding HBIO

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

EAM Global Investors's HBIO Position: Q4 2018 in Review

EAM Global Investors sold out of Harvard Bioscience (HBIO) in Q4 2018, closing a stake of 19,450 shares — an estimated $1.02M sold.

EAM Global Investors first reported a position in HBIO in Q3 2018 and held it in 1 quarter. The position peaked at $1.02M in Q3 2018. 80 funds tracked by Wall St. Rank hold HBIO as of Q4 2018.

  • EAM Global Investors reported no remaining Harvard Bioscience position as of Q4 2018 after selling out during the quarter.
  • EAM Global Investors sold 19,450 Harvard Bioscience shares in Q4 2018, an estimated $1.02M.
  • EAM Global Investors first reported a position in Harvard Bioscience in Q3 2018 and held it in 1 quarter.
  • EAM Global Investors's Harvard Bioscience position peaked at $1.02M in Q3 2018.
  • 80 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2018.

Based on EAM Global Investors's 13F filing for Q4 2018, filed 13 Feb 2019.